Literature DB >> 31617120

Lobe-Specific Lymph Node Dissection for Clinical Early-Stage (cIA) Peripheral Non-small Cell Lung Cancer Patients: What and How?

Han-Yu Deng1, Jie Zhou1, Ru-Lan Wang1, Rui Jiang1, Da-Xing Zhu1, Xiao-Jun Tang1, Qinghua Zhou2.   

Abstract

OBJECTIVE: We investigated the possible lobe-specific lymph node (LN) metastasis pattern of early-stage peripheral non-small cell lung cancers (NSCLC) and define the extent of lobe-specific LN dissection for them.
METHODS: We retrospectively collected clinical data of patients undergoing lobectomy or segmentectomy with systematic lymphadenectomy for clinical T1N0M0 peripheral NSCLC from January 2015 to December 2018. The LN metastasis pattern was analyzed by tumor lobe location.
RESULTS: A total of 590 patients were included for analysis. The mean number of total dissected LNs was 12.3 ± 5.8 and 8.2 ± 4.1 for total dissected mediastinal LNs. The rate of mediastinal LN metastasis was 9.5%. For cases of upper lobe tumor and lower lobe tumor, 8.8% and 6.0% of them respectively metastasized to the upper LN zone (P = 0.274). However, upper lobe tumors hardly metastasized to the subcarinal (0.3%) and lower (0.3%) LN zones while for lower lobe tumors, the rate of LN metastasis was 10.2% and 5.4% respectively (both P < 0.001). However, all cases (100%) metastasizing from lower lobes to the upper LN zone had a tumor size of 2-3 cm, whereas cases with a tumor size ≤ 2 cm had no metastasis (0%). None of the tumors in the right middle lobe metastasized to the lower LN zone (0%).
CONCLUSIONS: A lobe-specific LN metastasis pattern was observed in clinical stage IA peripheral NSCLC. For tumors in upper lobes (≤ 3 cm), there may be no need to dissect lower mediastinal LNs and for tumors in lower lobes (≤ 2 cm), dissecting upper mediastinal LNs may not be required.

Entities:  

Year:  2019        PMID: 31617120     DOI: 10.1245/s10434-019-07926-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  4 in total

1.  Evaluation of the necessity of Pulmonary Ligament Lymph Node Dissection for Upper Lobe Stage IB NSCLC: A Propensity Score-matched Study.

Authors:  Feng Wang; Xiangyang Yu; Yi Han; Lanjun Zhang; Shuku Liu
Journal:  J Cancer       Date:  2022-09-06       Impact factor: 4.478

2.  LobE-Specific lymph node diSsectiON for clinical early-stage non-small cell lung cancer: protocol for a randomised controlled trial (the LESSON trial).

Authors:  Weijia Huang; Han-Yu Deng; Zhi-Zhen Ren; Kai Xu; Yi-Feng Wang; Xiaojun Tang; Da-Xing Zhu; Qinghua Zhou
Journal:  BMJ Open       Date:  2022-08-29       Impact factor: 3.006

3.  Lobe-Specific Node Dissection Can Be a Suitable Alternative to Systematic Lymph Node Dissection in Highly Selective Early-Stage Non-Small-Cell Lung Cancer Patients: A Meta-Analysis.

Authors:  Zihuai Wang; Zhuoran Qi; Diou Cheng; Xiaohu Hao; Qiang Pu; Lunxu Liu
Journal:  Ann Thorac Cardiovasc Surg       Date:  2020-12-07       Impact factor: 1.520

4.  Intentional Segmentectomy for Clinical T1 N0 Non-small Cell Lung Cancer: Survival Differs by Segment.

Authors:  Gregory D Jones; Raul Caso; Giye Choe; Kay See Tan; James G Connolly; Joe Dycoco; Daniela Molena; Bernard J Park; James Huang; Prasad S Adusumilli; Matthew J Bott; Robert J Downey; William D Travis; David R Jones; Gaetano Rocco
Journal:  Ann Thorac Surg       Date:  2020-07-31       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.